title: Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
abstract: OBJECTIVE
  To identify differences in rheumatoid arthritis (RA) care costs and utilization among patients receiving therapy with leflunomide (LEF) or etanercept (ETA).
  
  
  METHODS
  A retrospective cohort analysis of patients diagnosed with RA and starting treatment with LEF or ETA.
  
  
  METHODS
  Patients diagnosed with RA and receiving newly prescribed LEF or ETA in 1998 were identified from a database containing patient-level medical and pharmaceutical claims. Patients were subsequently observed for 6 months. RA-related treatment charges during the observation period were compared between cohorts.
  
  
  RESULTS
  A total of 527 LEF- and 281 ETA-treated patients were identified. The 2 cohorts were comparable with respect to demographics, comorbid conditions, and concomitant medication use, although LEF recipients were, on average, older than ETA recipients (mean age 52.97 versus 48.43 years; P < .0001). ETA recipients had higher mean 6-month postdiagnosis charges than LEF recipients ($7722.01 +/- $5285.20 versus $3301.84 +/- $4054.75; P < .0001). This difference was primarily related to differences in RA-related pharmacy charges ($5877.78 +/- $2237.68 versus $1877.23 +/- $1258.05; P < .0001).
  
  
  CONCLUSIONS
  Compared with charges in the ETA group, RA care costs in the LEF group were significantly lower during the 6 months after the initiation of therapy. The difference in mean total RA-related charges was attributable mainly to the difference in RA-related pharmacy charges.
authors.affiliation: NDCHealth, 2394 East Camelback Road, Phoenix, AZ 85016, USA. cyrus.yazdani@ndchealth.com
authors.forename: C
authors.initials: C
authors.lastname: Yazdani
authors.forename: T
authors.initials: T
authors.lastname: McLaughlin
authors.forename: G
authors.initials: G
authors.lastname: Cummins
authors.forename: J
authors.initials: J
authors.lastname: Doyle
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D015331:Cohort Studies; D017281:Cost of Illness; D000068800:Etanercept; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use*; D007555:Isoxazoles / Q000191:economics / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014481:United States
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D000077339:Leflunomide; D000068800:Etanercept